“SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes”, d, vol. 4, no. 19, pp. 38–39, Jul. 2026, Accessed: Jul. 28, 2026. [Online]. Available: https://thediabzen.com/index.php/d/article/view/62